AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 10,000 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $54.00, for a total value of $540,000.00. Following the completion of the transaction, the insider directly owned 12,835 shares in the company, valued at $693,090. The trade was a 43.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB opened at $53.08 on Friday. The business has a fifty day moving average of $47.85 and a 200-day moving average of $35.59. AnaptysBio, Inc. has a twelve month low of $13.99 and a twelve month high of $57.65. The firm has a market cap of $1.47 billion, a PE ratio of -18.82 and a beta of 0.35.

AnaptysBio announced that its board has authorized a stock repurchase plan on Friday, November 21st that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, January 21st. UBS Group initiated coverage on shares of AnaptysBio in a research report on Wednesday, January 7th. They set a “buy” rating and a $70.00 target price on the stock. Barclays raised their price objective on shares of AnaptysBio from $55.00 to $78.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Finally, Truist Financial upped their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $66.89.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC grew its position in shares of AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 821 shares during the period. Larson Financial Group LLC boosted its holdings in shares of AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the period. Bessemer Group Inc. increased its position in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. boosted its position in shares of AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares during the period.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.